<DOC>
	<DOCNO>NCT00535782</DOCNO>
	<brief_summary>This 2 arm study investigate effect tocilizumab lipid , arterial stiffness , marker atherogenic risk patient moderate severe active rheumatoid arthritis . In Part 1 study , patient randomize receive either tocilizumab 8mg/kg intravenously placebo every 4 week , combination methotrexate 7.5-25 mg weekly . In Part 2 , patient receive open-label treatment tocilizumab plus methotrexate .</brief_summary>
	<brief_title>A Study Effect Tocilizumab Markers Atherogenic Risk Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , 1875 year age rheumatoid arthritis ( RA ) &gt; 6 month duration able receive outpatient treatment methotrexate least 12 week enter study , stable dose 7.525 mg/week last 8 week oral corticosteroid nonsteroidal antiinflammatory drug ( NSAIDS ) permit , stable dose 4 week study start Exclusion Criteria major surgery ( include joint surgery ) within 8 week prior screen , plan surgery within 6 month enter study history , current inflammatory joint disease rheumatic autoimmune disease RA inadequate response antitumor necrosis factor ( TNF ) agent 6 month prior baseline , inadequate response &gt; 2 antiTNF agent initiation treatment lipid lower agent within 12 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>